GPR50 can promote the HCC progression via the ligand-independent ADAM17-mediated Notch signaling pathway, which can provide insights into HCC progression and prognosis and development of Notch-based HCC treatment strategies. The gene discussed is ADAM17; the disease is hepatocellular carcinoma.